Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
作者信息
Shah N, Thall P F, Fox P S, Bashir Q, Shah J J, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat U R, Hosing C M, Cornelison A, Shpall E J, Orlowski R Z, Champlin R E, Qazilbash M H
机构信息
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27.
Abstract
摘要
相似文献
1
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27.
2
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.
3
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Biol Blood Marrow Transplant. 2017 Jun;23(6):930-937. doi: 10.1016/j.bbmt.2017.03.007. Epub 2017 Mar 8.
4
Autologous transplantation and maintenance therapy in multiple myeloma.
N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888.
5
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Clin Lymphoma Myeloma. 2006 May;6(6):475-7. doi: 10.3816/CLM.2006.n.028.
6
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Eur J Haematol. 2006 Apr;76(4):273-7. doi: 10.1111/j.1600-0609.2005.00610.x.
7
Multiple myeloma in the elderly: when to treat, when to go to transplant.
Oncology (Williston Park). 2010 Oct;24(11):992-8.
8
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):19-24. doi: 10.1016/j.clml.2012.08.009. Epub 2012 Nov 7.
9
[Hematopoietic stem cell transplantation for multiple myeloma].
Rinsho Ketsueki. 2009 Oct;50(10):1420-6.
10
引用本文的文献
1
CFO: Calibration-free odds design for phase I/II clinical trials.
Stat Methods Med Res. 2022 Jun;31(6):1051-1066. doi: 10.1177/09622802221079353. Epub 2022 Mar 3.
2
Implementing the EffTox dose-finding design in the Matchpoint trial.
BMC Med Res Methodol. 2017 Jul 20;17(1):112. doi: 10.1186/s12874-017-0381-x.
3
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Lancet Haematol. 2017 Jun;4(6):e283-e292. doi: 10.1016/S2352-3026(17)30080-7. Epub 2017 May 15.
4
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
Br J Haematol. 2017 May;177(3):457-466. doi: 10.1111/bjh.14570. Epub 2017 Mar 14.
5
Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells.
Blood Cancer J. 2016 Oct 7;6(10):e480. doi: 10.1038/bcj.2016.92.
6
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2016 Dec;22(12):2159-2164. doi: 10.1016/j.bbmt.2016.09.003. Epub 2016 Sep 13.
本文引用的文献
1
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2014 Jul;15(8):874-85. doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16.
2
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Semin Oncol. 2013 Oct;40(5):634-51. doi: 10.1053/j.seminoncol.2013.07.007.
3
Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.
Leuk Lymphoma. 2013 Oct;54(10):2200-4. doi: 10.3109/10428194.2013.773998. Epub 2013 Mar 4.
4
Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
Biol Blood Marrow Transplant. 2013 Mar;19(3):445-9. doi: 10.1016/j.bbmt.2012.11.013. Epub 2012 Nov 24.
5
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
Leuk Lymphoma. 2013 Jul;54(7):1465-72. doi: 10.3109/10428194.2012.746682. Epub 2012 Dec 14.
6
Durable remission with salvage second autotransplants in patients with multiple myeloma.
Cancer. 2012 Jul 15;118(14):3549-55. doi: 10.1002/cncr.26662. Epub 2011 Nov 15.
7
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29.
8
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Am J Hematol. 2011 Aug;86(8):640-5. doi: 10.1002/ajh.22053. Epub 2011 May 31.
9
Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
Br J Haematol. 2010 Jan;148(2):335-7. doi: 10.1111/j.1365-2141.2009.07931.x.
10
International uniform response criteria for multiple myeloma.
Leukemia. 2006 Sep;20(9):1467-73. doi: 10.1038/sj.leu.2404284. Epub 2006 Jul 20.
Zotero 插件